Wyeth Pharmaceuticals, a division of Wyeth, and Progenics Pharmaceuticals have received Fast Track designation from the FDA for their application of the intravenous form of methylnaltrexone, which is being investigated for the treatment of postoperative ileus. The FDA Fast Track designation facilitates development and expedites regulatory review of drugs that the FDA recognizes to potentially address an unmet medical need for serious or life-threatening conditions. Methylnaltrexone is an inve...